In this podcast, Jesse Roman, MD, provides an overview of new resources for clinicians on managing progressive fibrosing interstitial lung disease and connective tissue-related interstitial lung disease, including clinical presentation, prevalence, potential risk factors, genetic factors, and diagnosis, and management.

Jesse Roman, MD, on New Interstitial Lung Disease Primers

In this episode, Arthur Kavanaugh, MD, explains what is new in psoriatic arthritis (PsA) in 2022, including new treatments, new treatment approaches, updates in the diagnosis PsA, and in safety considerations. Dr Kavanaugh presented this topic at the Congress of Clinical Rheumatology in Destin, Florida on May 11, 2022.

2022: What is New in Psoriatic Arthritis?

Newsletters were a big theme of this year's conference. Kira Hoffelmeyer walks us through newsletter best practices and ways to push the boundaries.

#ONA22 - So You Want A Better Newsletter?

In this podcast, Eric D. Shah, MD, MBA, speaks about his team's study that analyzed the cost-benefit outcomes for patients with IBS-D, how their findings can impact clinical practice when choosing the best treatment for patients, and what options are out there for clinicians and patients to consider.

Comparing Cost, Outcomes of IBS-D Treatments

In this podcast, Daniel Kuritzkes, MD, speaks about new medications available, choosing a new regimen for, and defining patients with HIV and limited treatment options. Dr Kuritzkez also participated in a symposium on these topics titled "Managing HIV Patients With Limited Treatment Options" at IDWeek 2022.

Choosing a New Treatment Regimen for Patients With HIV

In this podcast, James Matera, DO, speaks about a patient case presentation of a 41-year-old man with a recurrence of minimal change disease and an incidental finding of papillary renal cell carcinoma on renal biopsy.

Incidental Finding of Papillary Renal Cell Carcinoma on Renal Biopsy

In this podcast, Joëlle E. Vergroesen, MSc, discusses the results of her team's study examining how the use of metformin, insulin, and sulfonylurea derivatives may impact the risk of open-angle glaucoma, age-related macular degeneration (AMD), and cataracts among individuals with type 2 diabetes.

Diabetes Medication Use and Common Eye Disorders

Consultant360 spoke with Viral Shah MD, Professor of Medicine in the Division of Endocrinology and Metabolism at the Indiana University School of Medicine, and Chair of the ADA Diabetes Technology Interest Group. 

We spoke with Dr. Shah to discuss new advancements in the field of diabetes technology, what excites him about diabetes technology when looking ahead, and more.

What is the ADA Diabetes Technology Interest Group?

In this podcast, Evan Brickner and Trini Mathew, MD, MPH, discuss their latest research paper on evaluating for alcohol use disorder among patients with HIV in their primary care clinic, how other clinicians can implement this screening tool, and the impacts that screening can have on patients' well-being.  More at www.consultant360.com/infectious-diseases

Expert Conversations: Using an Alcohol Screening Tool for HIV Patients

In this podcast, Talia Segal and Michael Waxman, MD, MPH, talk about their research that investigated the demographics of patients with hepatitis C virus (HCV) before and after the US Preventive Services Task Force updated its screening guidelines. More at www.consultant360.com

Expert Conversations: Expanding HCV Screening to Include Tough-to-Reach Populations

Podcasts360, powered by Consultant360, features short interviews with medical professionals about current research, news, and general information for health care providers in 35+ specialties.

What is the ADA Diabetes Technology Interest Group?

Podcasts360

Related tracks